BioSpace News Archive

GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, announced the publication of its Extra-Financial Performance Report 2022.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter of 2023.

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2023 financial results on Thursday, May 4, 2023 after the close of the U.S. financial markets.

Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Bank of America Securities 2023 Health Care Conference on May 11 at 10:00 a.m. P.T. / 1:00 p.m. E.T. Ben Hickey, chief commercial officer, will represent the company in a fireside chat at the conference.

InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”) announced today it will issue first quarter 2023 financial results on Thursday, May 4, 2023, before the market opens.

Tempest Therapeutics, Inc. (Nasdaq: TPST) today announced the company plans to report early data from its Phase 1b/2 combination study of TPST-1120 in first-line hepatocellular carcinoma in a premarket press release and webcast Friday, April 28, 2023.

DURECT Corporation announced it will host a Key Opinion Leader event on Alcohol-Associated Hepatitis on May 16th in New York City.

Vanda Pharmaceuticals Inc. announced it will release results for the first quarter 2023 on Wednesday, May 3, 2023, after the market closes.

Globus Medical, Inc. announced that at the special meeting of shareholders held earlier today its shareholders voted to approve the issuance of shares of Globus Medical Class A common stock in connection with the proposed merger with NuVasive.

Aditum Bio, the biotech investment firm cofounded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research Dr. Mark Fishman, announced the formation of Vitalli Bio, a portfolio company created for the development of novel therapies for immunological disorders.